Shigella Infections (Shigellosis)-Pipeline Review, H2 2015

Shigella Infections (Shigellosis)-Pipeline Review, H2 2015


  • Products Id :- GMDHC7257IDB
  • |
  • Pages: 50
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Shigella Infections (Shigellosis)-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Shigella Infections (Shigellosis)-Pipeline Review, H2 2015', provides an overview of the Shigella Infections (Shigellosis)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Shigella Infections (Shigellosis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Shigella Infections (Shigellosis) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Shigella Infections (Shigellosis)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Shigella Infections (Shigellosis) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Shigella Infections (Shigellosis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Shigella Infections (Shigellosis) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Shigella Infections (Shigellosis)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Shigella Infections (Shigellosis) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Shigella Infections (Shigellosis) Overview 7

Therapeutics Development 8

Pipeline Products for Shigella Infections (Shigellosis)-Overview 8

Pipeline Products for Shigella Infections (Shigellosis)-Comparative Analysis 9

Shigella Infections (Shigellosis)-Therapeutics under Development by Companies 10

Shigella Infections (Shigellosis)-Therapeutics under Investigation by Universities/Institutes 11

Shigella Infections (Shigellosis)-Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Shigella Infections (Shigellosis)-Products under Development by Companies 14

Shigella Infections (Shigellosis)-Products under Investigation by Universities/Institutes 15

Shigella Infections (Shigellosis)-Companies Involved in Therapeutics Development 16

Anacor Pharmaceuticals, Inc. 16

GlaxoSmithKline Plc 17

Protein Potential, LLC 18

Shigella Infections (Shigellosis)-Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Combination Products 20

Assessment by Target 21

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Drug Profiles 27

1790GAHB-Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

GVXNSD-133-Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

INX-201-Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

KKL-35-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

SC-599-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

SE-1-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

shigella vaccine-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

shigella vaccine-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Shigella Vaccine-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

shigella vaccine 1-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Shigetec-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Small Molecule for Shigellosis-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

typhoid + shigella vaccine-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Shigella Infections (Shigellosis)-Recent Pipeline Updates 41

Shigella Infections (Shigellosis)-Dormant Projects 42

Shigella Infections (Shigellosis)-Discontinued Products 43

Shigella Infections (Shigellosis)-Product Development Milestones 44

Featured News & Press Releases 44

Jul 29, 2013: GlycoVaxyn Secures CHF 5.1 Million Strategic Translation Award From the Wellcome Trust to Finance Clinical Development of Shigella Vaccine 44

Feb 20, 2013: NIH-Funded Researchers Begin Trial of Shigella Vaccine Candidates 44

Jan 27, 2012: IVI Granted Two U.S. Patents On Dysentery Vaccine Inventions 45

Oct 08, 2010: GlycoVaxyn Phase I Clinical Study Shows Positive Data With Shigella Dysenteriae Vaccine Candidate Against Severe Diarrheal Disease 46

Feb 23, 2010: GlycoVaxyn Initiates Phase I Clinical Study with Bioconjugate Vaccine 47

Feb 15, 2007: IVI Scientists Develop New Laboratory Animal Model For Shigella 47

Appendix 49

Methodology 49

Coverage 49

Secondary Research 49

Primary Research 49

Expert Panel Validation 49

Contact Us 49

Disclaimer 50

List of Tables

Number of Products under Development for Shigella Infections (Shigellosis), H2 2015 8

Number of Products under Development for Shigella Infections (Shigellosis)-Comparative Analysis, H2 2015 9

Number of Products under Development by Companies, H2 2015 10

Number of Products under Investigation by Universities/Institutes, H2 2015 11

Comparative Analysis by Clinical Stage Development, H2 2015 12

Comparative Analysis by Early Stage Development, H2 2015 13

Products under Development by Companies, H2 2015 14

Products under Investigation by Universities/Institutes, H2 2015 15

Shigella Infections (Shigellosis)-Pipeline by Anacor Pharmaceuticals, Inc., H2 2015 16

Shigella Infections (Shigellosis)-Pipeline by GlaxoSmithKline Plc, H2 2015 17

Shigella Infections (Shigellosis)-Pipeline by Protein Potential, LLC, H2 2015 18

Assessment by Monotherapy Products, H2 2015 19

Assessment by Combination Products, H2 2015 20

Number of Products by Stage and Target, H2 2015 22

Number of Products by Stage and Route of Administration, H2 2015 24

Number of Products by Stage and Molecule Type, H2 2015 26

Shigella Infections (Shigellosis) Therapeutics-Recent Pipeline Updates, H2 2015 41

Shigella Infections (Shigellosis)-Dormant Projects, H2 2015 42

Shigella Infections (Shigellosis)-Discontinued Products, H2 2015 43

List of Figures

Number of Products under Development for Shigella Infections (Shigellosis), H2 2015 8

Number of Products under Development for Shigella Infections (Shigellosis)-Comparative Analysis, H2 2015 9

Number of Products under Development by Companies, H2 2015 10

Number of Products under Investigation by Universities/Institutes, H2 2015 11

Comparative Analysis by Clinical Stage Development, H2 2015 12

Comparative Analysis by Early Stage Products, H2 2015 13

Assessment by Monotherapy Products, H2 2015 19

Number of Products by Top 10 Targets, H2 2015 21

Number of Products by Stage and Top 10 Targets, H2 2015 21

Number of Products by Top 10 Routes of Administration, H2 2015 23

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 23

Number of Products by Top 10 Molecule Types, H2 2015 25

Number of Products by Stage and Top 10 Molecule Types, H2 2015 25

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Anacor Pharmaceuticals, Inc.

GlaxoSmithKline Plc

Protein Potential, LLC

Shigella Infections (Shigellosis) Therapeutic Products under Development, Key Players in Shigella Infections (Shigellosis) Therapeutics, Shigella Infections (Shigellosis) Pipeline Overview, Shigella Infections (Shigellosis) Pipeline, Shigella Infections (Shigellosis) Pipeline Assessment

select a license

Single User License
USD 2000 INR 128320
Site License
USD 4000 INR 256640
Corporate User License
USD 6000 INR 384960

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com